Niels Tørring

M.Sc. Ph.D, Klinisk lektor, Lektor

Profile photo

Niels Tørring

Klinisk lektor, Lektor

  • Institut for Klinisk Medicin - Blodprøver og Biokemi
  • Institut for Klinisk Medicin - Blodprøver og Biokemi
Postaddresse:
Palle Juul-Jensens Boulevard 69
8200
Aarhus N
Danmark
Postaddresse:
Palle Juul-Jensens Boulevard 99
8200
Aarhus N
Danmark

E-mail: nto@clin.au.dk

Telefon: +4540465710

Publikationer

Functional autoantibodies against Endothelin-1 receptor type A and Angiotensin II receptor type 1 in patients with preeclampsia

Buttrup Larsen, S., Wallukat, G., Schimke, I., Sandager, A., Tvilum Christensen, T., Uldbjerg, N. & Tørring, N., 1 okt. 2018, I : Pregnancy Hypertension. 14, s. 189-194 6 s.

The Impact of the Biological Variability or Assay Performance on AMH Measurements: A Prospective Cohort Study With AMH Tested on Three Analytical Assay-Platforms

Bungum, L., Tagevi, J., Jokubkiene, L., Bungum, M., Giwercman, A., Macklon, N., Andersen, C. Y., Klausen, T. W., Tørring, N., Kumar, A. & Skouby, S. O., okt. 2018, I : Frontiers in Endocrinology. 9, s. 603

Prediction of severe pre-eclampsia by a combination of sFlt-1, CT-pro ET1 and blood pressure: exploratory study

Malte, A. L., Uldbjerg, N., Wright, D. & Tørring, N., 5 jun. 2018, I : Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 51, s. 768-774 7 s.

The impact of pneumatic tube transport on whole blood coagulation and platelet function assays

Nissen, P. H., Wulff, D. E., Tørring, N. & Hvas, A-M., jun. 2018, I : Platelets. 29, 4, s. 421-424 4 s.

Prevalence of xenobiotic substances in first-trimester blood samples from Danish pregnant women: a cross-sectional study

Aagaard, S., Larsen, A., Andreasen, M. F., Lesnikova, I., Telving, R., Vestergaard, A. L. C., Tørring, N., Uldbjerg, N. & Bor, I. P., 2018, I : B M J Open. 8, 3, 7 s., e018390.

First trimester serum levels of the soluble transcobalamin receptor, holo-transcobalamin, and total transcobalamin in relation to preeclampsia risk

Abuyaman, O., Torring, N., Obeid, R. & Nexo, E., dec. 2016, I : Scandinavian Journal of Clinical & Laboratory Investigation. 76, 8, s. 641-644 4 s.

First trimester combined screening - focus on early biochemistry

Tørring, N., 12 jul. 2016, I : Scandinavian Journal of Clinical and Laboratory Investigation. Supplement. 76, 6, s. 435-447 13 s.

First trimester screening for other trisomies than trisomy 21, 18 and 13

Tørring, N., Petersen, O. B., Becher, N., Vogel, I., Uldbjerg, N. & the Danish Fetal Medicine Study Group, jun. 2015, I : Prenatal Diagnosis. 35, 6, s. 612-19 8 s.

Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial

Madsen, H. N., Lauszus, F., Trolle, G. B., Ingerslev, H. J. & Tørring, N., maj 2015, I : Acta Obstetricia et Gynecologica Scandinavica. 94, 5, s. 547-51 5 s.

Antimüllersk hormon er et klinisk anvendeligt mål for ovariereserve

Hyldgaard, J. M., Ingerslev, H. J., Tørring, N., Madsen, H. N. & Bor, I. P., 26 jan. 2015, I : Ugeskrift for Laeger. 177, 5, s. 2-5 V09140477.

Ten Years of Experience with First-Trimester Screening for Fetal Aneuploidy Employing Biochemistry from Gestational Weeks 6+0 to 13+6

Tørring, N., Petersen, O. B. & Uldbjerg, N., jan. 2015, I : Fetal Diagnosis and Therapy. 37, 1, s. 51-57 7 s.

Comparison of two different methods for measuring anti-mullerian hormone in a clinical series

Hyldgaard, J., Bor, I. P., Ingerslev, H. J. & Tørring, N., 2015, I : Reproductive Biology and Endocrinology. 13, 1, 107.

CLINICAL PERFORMANCE CHARACTERISTICS OF ELECSYS® FREE-ΒHCG AND PAPP-A FOR FIRST TRIMESTER TRISOMY 21 RISK ASSESSMENT IN GESTATIONAL WEEKS 8+0 TO 14+0

Tørring, N., aulesa, C., Eiben, B., Luppa, P., Ortiz, J. U., Ferri, M., Sancken, U., Vereecken, A., Wiedemann, U., Zitzler, J. & Nicolaides, K. H., 5 jun. 2014. 1 s.

Autocorrelation and cross correlation between free hCGβ and PAPP-A in repeated sampling during first trimester of pregnancy

Nørgaard, P., Wright, D., Ball, S., Newell, P., Kirkegaard, I., Petersen, O. B., Uldbjerg, N., Tørring, N., Jørgensen, F. S., Friis-Hansen, L. J., Ekelund, C. K., Tabor, A. & Sørsensen, S., sep. 2013, I : Clinical Chemistry and Laboratory Medicine. 51, 9, s. 1781-8 8 s.

A prospective study evaluating the performance of first trimester combined screening for trisomy 21 using repeated sampling of the maternal serum markers PAPP-A and free β-hCG

Ekelund, C. K., Wright, D., Ball, S., Kirkegaard, I., Nørgaard, P., Sørensen, S., Friis-Hansen, L. J., Jørgensen, F. S., Tørring, N., Bech, B. H., Petersen, O. B. & Tabor, A., sep. 2012, I : Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 40, 3, s. 276-281 6 s.

Downregulation of ZNF132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis

Abildgaard, M. O., Borre, M., Mørck Mortensen, M., Ulhøi, B. P., Tørring, N., Wild, P., Kristensen, H., Mansilla, F., Ottosen, P. D., Andersen, L. D., Orntoft, T. F. & Dalsgaard Sørensen, K., 15 feb. 2012, I : International Journal of Cancer. 130, 4, s. 885-895 11 s.

Impact of type 1 diabetes and glycemic control on fetal aneuploidy biochemical markers

Madsen, H. N., Ekelund, C. K., Tørring, N., Ovesen, P. G., Friis-Hansen, L., Ringholm Nielsen, L. & Petersen, O. B., jan. 2012, I : Acta Obstetricia et Gynecologica Scandinavica. 91, 1, s. 57-61 5 s.

OC15.03: Effects of gestational age at biochemical sampling on first-trimester screening performance for trisomy 18 and 13

Kirkegaard, I., Ekelund, C. K., Ball, S., Newell, P., Wright, D., Noergaard, P., Soerensen, S., Friis-Hansen, L. J., Toerring, N., Uldbjerg, N., Tabor, A., Petersen, O. B. & Jørgensen, F. S., 2012, I : Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 40, S1, s. 31-31 1 s.

OC15.04: Operator-specific PAPP-A and free beta-hCG MoM values as a method of individual audit of CRL measurements at the NT scan. National data from 171,469 pregnancies

Newell, P., Ball, S., Wright, D., Kirkegaard, I., Uldbjerg, N., Tørring, N., Ekelund, C. K., Friis-Hansen, L. J., Nørgaard, P., Sørensen, S., Jørgensen, F. S., Tabor, A. & Petersen, O. B., 2012, I : Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 40, S1, s. 31-31 1 s.

OP23.01: A prospective study evaluating the performance of first trimester combined screening for trisomy 21 using repeated sampling of the maternal serum markers PAPP-A and free β-hCG

Ekelund, C. K., Wright, D., Ball, S., Kirkegaard, I., Nørgaard, P., Jørgensen, F. S., Sørensen, S., Friis-Hansen, L. J., Toerring, N., Bech, B. H., Petersen, O. B. & Tabor, A., 2012, I : Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 40, S1, s. 122-123 2 s.

OP23.06: Effects of method of conception and gestational age on first trimester biochemical markers

Nørgaard, P., Ball, S., Newell, P., Ekelund, C. K., Kirkegaard, I., Uldbjerg, N., Tørring, N., Jørgensen, F., Sørensen, S., Friis-Hansen, L. J., Petersen, O. B., Wright, D. & Tabor, A., 2012, I : Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 40, S1, s. 124-124 1 s.

PAPP-A and free β-hCG measured prior to 10 weeks is associated with preterm delivery and small-for-gestational-age infants

Kirkegaard, I., Henriksen, T. B., Tørring, N. & Uldbjerg, N., 4 jan. 2011, I : Prenatal Diagnosis. 31, 2, s. 171-175 5 s.

A re-assessment of biochemical marker distributions in T21 affected and unaffected twin pregnancies in the first trimester

Madsen, H. N., Ball, S., Wright, D., Tørring, N., Petersen, O. B., Nicolaides, K. & Spencer, K., jan. 2011, I : Ultrasound in Obstetrics & Gynecology. 37, 1, s. 38-47 10 s.

Early first-trimester maternal serum placental growth factor (PlGF) in trisomy 21 pregnancies

Nj, C., A, S., Tørring, N. & K, S., 2011, I : Ultrasound in Obstetrics & Gynecology.

Low PAPP-A in the first trimester is associated with reduced fetal growth rate prior to gestational week 20

Salvig, J. D., Kirkegaard, I., Winding, T. N., Henriksen, T. B., Tørring, N. & Uldbjerg, N., 1 jun. 2010, I : Prenatal Diagnosis. 30, 6, s. 503-8 6 s.

First trimester screening in gestational weeks 6 and 7

Madsen, H. N. & Tørring, N., 2010, I : Acta Obstetricia et Gynecologica Scandinavica, Supplement.

First trimester screening for trisomy 21 in gestational week 8-10 by ADAM12-S as a maternal serum marker

Tørring, N., Ball, S., Wright, D., Sarkissian, G., Guitton, M. & Darbouret, B., 2010, I : Reproductive Biology and Endocrinology. 8, s. 129

First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation

Wright, D., Spencer, K., Kagan K, K., Tørring, N., Petersen, O. B., Christou, A., Kallikas, J. & Nicolaides, K. H., 2010, I : Ultrasound in Obstetrics & Gynecology. 36, 4, s. 404-11 7 s.

PAPP-A, free β-hCG, and early fetal growth identify two pathways leading to preterm delivery

Kirkegaard, I., Uldbjerg, N., Petersen, O. B., Tørring, N. & Henriksen, T. B., 2010, I : Prenatal Diagnosis. 30, 10, s. 956-63 7 s.

Promoter hypomethylation and upregulation of trefoil factors in prostate cancer

Vestergaard, E. M., Nexø, E., Tørring, N., Borre, M., Ørntoft, T. F. & Sørensen, K. D., 2010, I : International Journal of Cancer. 127, 8, s. 1857-65 8 s.

Screening for fetal trisomy 21 in gestational weeks 6 and 7

Madsen, H. N., Petersen, O. B. & Tørring, N., 2010, I : Acta Obstetricia et Gynecologica Scandinavica. 89, 9, s. 1218-21 4 s.

Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy

Sørensen, K. D., Wild, P. J., Mortezavi, A., Adolf, K., Tørring, N., Heebøll, S., Ulhøi, B. P., Ottosen, P., Sulser, T., Hermanns, T., Moch, H., Borre, M., Ørntoft, T. F. & Dyrskjøt, L., 2009, I : Clinical Cancer Research. 15, 4, s. 1400-1410 10 s.

Performance of First-trimester Screening Between Gestational week 7+5 and 13+6

Tørring, N., 2009, I : Open Clinical Chemistry Journal. 55, 8, s. 1564-8 4 s.

Performance of first-trimester combined screening for trisomy 13 and 18 with the double test taken at a gestational age of 8 + 0 to 13 + 6

Kirkegaard, I., Petersen, O. B., Uldbjerg, N. & Tørring, N., 2009, I : Prenatal Diagnosis. 29, 6, s. 582-7 5 s.

Snai1 is over-expressed in Prostate Cancer.

Heebøll, S., Borre, M., Ottosen, P., Andersen, L. D., Ørntoft, T. F. & Tørring, N., 2009, I : Acta Pathologica Microbiologica et Immunologica Scandinavica. 117, s. 196-204 9 s.

Snail1 is over-expressed in prostate cancer

Heebøll, S., Borre, M., Ottosen, P. D., Dyrskjøt, L., Tørring, N. & Ørntoft, T. F., 2009, I : Acta Pathologica Microbiologica et Immunologica Scandinavica. 117, 3, s. 196-204 8 s.

Improved performance of first-trimester combined screening for trisomy 21 with the double test taken before a gestational age of 10 weeks

Kirkegaard, I., Petersen, O. B., Uldbjerg, N. & Tørring, N., 1 sep. 2008, I : Prenatal Diagnosis. 28, 9, s. 839-44 6 s.

First-trimester ADAM12s as early markers of trisomy 21: a promise still unfulfilled?

Spencer, K., Cowans, N. J., Uldbjerg, N. & Tørring, N., 1 apr. 2008, I : Prenatal Diagnosis. 28, 4, s. 338-42 5 s.

Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer

Sørensen, K. D., Borre, M., Ørntoft, T. F., Andersen, L. D. & Tørring, N., 1 feb. 2008, I : International Journal of Cancer. 122, 3, s. 509-19 11 s.

Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis

Thorsen, K., Sørensen, K. D., Brems-Eskildsen, A. S., Modin, C., Gaustadnes, M., Hein, A-M. K., Kruhøffer, M., Laurberg, S., Borre, M., Wang, K., Brunak, S., Krainer, A. R., Tørring, N., Dyrskjøt, L., Andersen, C. L. & Ørntoft, T. F., 2008, I : Molecular and Cellular Proteomics. 7, 7, s. 1214-24 10 s.

First trimester intact hCG as an early marker of trisomy 21: a promise unrecognised?

Spencer, K., Cowans, N. J., Uldbjerg, N., Vereecken, A. & Tørring, N., 2008, I : Prenatal Diagnosis. 28, 12, s. 1156-9 3 s.

First-trimester ADAM12s as early markers of trisomy 21: a promise still unfulfilled?

Spencer, K., Cowans, NJ., Uldbjerg, N. & Tørring, N., 2008, I : Prenatal Diagnosis. 28, 4, s. 338-42 5 s.

Praenatal diagnostik i Arhus og Viborg Amter efter implementering af første trimester-risikovurdering

Tørring, N., Jølving, L. R., Petersen, O. B. B., Holmskov, A., Hertz, J. M. & Uldbjerg, N., 2008, I : Ugeskrift for Laeger. 170, 1, s. 50-4 4 s.

Prænatal Diagnostik i Århus og Viborg amter efter Implementering af Første Trimester Risikovurdering

Tørring, N., Uldbjerg, N., Jølving, L. R., Petersen, O. B., Hertz, J. M. & Holmskov, A., 2008, I : Ugeskrift for Laeger. 170, 1, s. 50-54 5 s.

Prænataldiagnostik i Århus og Viborg Amter efter implementering af første trimester-risikovurdering

Tørring, N., Holmskov, A., Hertz, J. M., Uldbjerg, N., Petersen, O. B. & Jølving, L. R., 2008, I : Ugeskrift for Laeger. 170, 1, s. 50-54 4 s.

SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation

Heebøll, S., Borre, M., Ottosen, P. D., Andersen, C. L., Mansilla, F., Dyrskjøt, L., Ørntoft, T. F. & Tørring, N., 2008, I : Histology and Histopathology. 23, 9, s. 1069-76 7 s.

A Hidden Markov Model to estimate population mixture and allelic copy-numbers in cancers using Affymetrix SNP arrays

Lamy, P., Andersen, C. L., Andersen, L. D., Tørring, N. & Wiuf, C., 2007, I : B M C Bioinformatics. 8, 434

Genome-Wide analysis of allelic imbalance in laser microdissected prostate cancer tissue using the Affymetrix 50K Mapping array identifies genomic patterns associated with metastasis and differentiation

Tørring, N., Borre, M., Sørensen, K., Andersen, C. L., Wiuf, C. & Ørntoft, T. F., 2007, I : British Journal of Cancer. 96, 3, s. 499-506 8 s.

Secretagogin is a new neuroendocrine marker in the human prostate

Adolf, K., Wagner, L., Bergh, A., Stattin, P., Ottosen, P., Borre, M., Birkenkamp-Demtröder, K., Ørntoft, T. F. & Tørring, N., 2007, I : Prostate. 67, 5, s. 472-484 13 s.

Plasma Trefoil Factors in prostate adenocarcinoma.

Vestergaard, E. M., Borre, M., Tørring, N., Poulsen, S. S. & Nexø, E., 2006, I : Clinical Cancer Research. 12, 3, s. 807-812 6 s.

Plasma levels of trefoil factors are increased in patients with advanced prostate cancer

Vestergaard, E. M., Borre, M., Poulsen, S. S., Nexø, E. & Tørring, N., 2006, I : Clinical Cancer Research. s. 807-812 6 s.

Validation of the use of DNA pools and primer extension in association studies of sporadic colorectal cancer for selection of candidate SNPs

Gaustadnes, M., Ørntoft, T. F., Jensen, J. L. & Tørring, N., 2006, I : Human Mutation. 27, 2, s. 187-194 8 s.

 Are microRNAs located in cancer specific regions in the genome?

Lamy, P., Andersen, C. L., Andersen, L. D., Tørring, N., Ørntoft, T. F. & Wiuf, C., 2006, I : British Journal of Cancer. 95, 10, s. 1415-8 4 s.

Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study

Lund, L., Møller Ernst-Jensen, K., Tørring, N. & Erik, N. J., 2005, I : Scandinavian Journal of Urology and Nephrology. 39, 2

Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition

Tørring, N., Dagnæs-Hansen, F., Sørensen, B. S., Ørntoft, T. F. & Nexø, E., 2005, I : Prostate. 64, 1, s. 1-8

The DNA damaging agent VP16 induces the expression a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced.

Sørensen, B. S., Tørring, N., Bor, M. V. & Nexø, E., 2004, I : Molecular and Cellular Biochemistry. 260, s. 129-135 7 s.

The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced

Sørensen, B. S., Tørring, N., Bor, M. V. & Nexø, E., 2004, I : Molecular and Cellular Biochemistry. 260, s. 129-135 7 s.

EGF-receptor inhibition - a new type of cancer treatment.

Nexø, E., Tørring, N. & Sørensen, B. S., 2002, I : Ugeskrift for Laeger. 164, 4, s. 777 1 s.

Effects of finasteride on vascular endothelial growth factor

Häggström, S., Tørring, N., Møller, K., Jensen, E., Lund, L., Nielsen, J. E., Bergh, A. & Damber, J-E., 2002, I : Scandinavian Journal of Urology and Nephrology. 36, s. 182-187 6 s.

Effects of finasteride on vascular endothelial growth factor

Haggstrom, S., Tørring, N., Jensen, K. M-E., Lund, L., Nielsen, J. E., Bergh, A. & Damber, J. E., 2002, I : Scandinavial Journal of Urology and Nephrology. 36, 3, s. 182-7 6 s.

Possible autocrine loop of epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo - controlled randomized study

Tørring, N., Jensen, K. M-E., Lund, L., Nielsen, J. E., Djurhuus, J. C., Poulsen, S. S. & Nexø, E., 2002, I : B J U International (Print). 89, 6, s. 583-90 8 s.

Chronic Treatment with Epidermal Growth Factor Induces Growth of the Rat Ventral Prostate

Tørring, N., Wen, J. G., Vinter-Jensen, L., Sørensen, F. B., Djurhuus, J. C. & Nexø, E., 2001, I : Scandinavian Journal of Urology and Nephrology. 35, 5, s. 339-344 6 s.

Early Urinary Changes in Tamm-Horsfall Protein and Epidermal Growth Factor in Diabetic Children.

Holmquist, P., Torffvit, O., Jørgensen, P., Tørring, N., Nexø, E. & Sjøblad, S., 2001, I : Pediatric Nephrology. 16, 6, s. 488-492 5 s.

Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.

Tørring, N., Sørensen, B. S. & Nexø, E., 2000, I : Anticancer Research. 20, 1A, s. 91-95 5 s.

Quantitation of the mRNA expression of the EGF-system. Selective induction of HB-EGF and Amphiregulin Expression by Growth Factor Stimulation of Prostate Stromal Cells.

Sørensen, B. S., Tørring, N., Bor, M. V. & Nexø, E., 2000, I : Translational Research. 136, 3, s. 209-217 9 s.

Systemic treatment with Epidermal Growth Factor (EGF)but not Insulin like Growth Factor (IGF-I) decrease the involution of the Prostate in Castrated Rats.

Tørring, N., Lars, V-J., Sørensen, F. B., Flyvbjerg, A. & Nexø, E., 2000, I : Urological Research. 20, 2, s. 75-81 6 s.

Amphiregulin is expressed in primary cultures of prostate myofibroblasts, epithelial cells and in prostate tissue.

Tørring, N., Sørensen, B. S., Boesch, S., Klocker, H. & Nexø, E., 1998, I : Prostate Cancer and Prostatic Diseases. 5, s. 262-267 6 s.

Epidermal Growth Factor in the rat prostate

Tørring, N., Jørgensen, P., Steen Seier, P. & Nexø, E., 1998, I : Prostate. 35, s. 35-42 8 s.

Prostata Cancer? Mamma Cancer? Do you know your serum IGF-I

Tørring, N., Ørskov, H. & Nexø, E., 1998, I : Ugeskrift for Laeger. 160, 31, s. 4541-4542 2 s.

Systemic administration of Insulin-like growth factor I (IGF-I) causes growth of the prostate

Tørring, N., 1997, I : Journal of Urology. 158, s. 222-227 6 s.

Why does the Prostate grow? Possible role of growth factors for development of Benigh Prostatic Hyperliasia.

Tørring, N. & Nexø, E., 1997, I : Ugeskrift for Laeger. 159, 19, s. 2833-35 3 s.